← Leaderboards
Hugh D Robertson
Weill Medical College Of Cornell Univ
$1,284,819
Attributed
$1,284,819
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,284,819 · 1
By mechanism
R01$1,284,819 · 1
Top collaborators
No co-investigators on record.
Most similar at Weill Medical College Of Cornell Univ
Same institution · by research overlap
- John P Moore$51,152,802
- Anne Muesch$8,797,862
- Stefano Rivella$10,978,618
- Philip L Leopold$4,978,121
- Robert J Kaner$13,023,117
Others in their field
Top investigators on “Antiviral Agents”
- Constance Ann Benson · University Of California, San Diego$209,152,068
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$120,325,769
- Judith S. Currier · University Of California Los Angeles$102,391,456
- Beth Baseler · Leidos Biomedical Research, Inc.$83,440,795
- Sharon A Nachman · Johns Hopkins University$77,262,665
- John Damon Chodera · Sloan-Kettering Inst Can Research$58,660,403
Research focus
Antiviral AgentsBinding SitesCrosslinkGenetic MappingHepatitis C VirusLiver CellsNucleic Acid SequenceProtein BiosynthesisProtein Signal SequenceRibonuclease IiiRibosomesRibozymesRnase Protection AssayVirus GeneticsVirus Infection MechanismVirus MorphologyVirus ProteinVirus Rna
Grant awards (4)
HCV INTERNAL RIBOSOME ENTRY SITE AS TARGET FOR THERAPY$335,583
R01 · FY2003 · DK
HCV INTERNAL RIBOSOME ENTRY SITE AS TARGET FOR THERAPY$325,809
R01 · FY2002 · DK
HCV INTERNAL RIBOSOME ENTRY SITE AS TARGET FOR THERAPY$316,321
R01 · FY2001 · DK
HCV INTERNAL RIBOSOME ENTRY SITE AS TARGET FOR THERAPY$307,106
R01 · FY2000 · DK